Over a third of treatment-seekers from São Paulo's Crackland report recent use of synthetic cannabinoids

Affiliations

¹ Associação Paulista para o Desenvolvimento da Medicina (SPDM), São Paulo, SP, Brazil. Departamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
² Associação Paulista para o Desenvolvimento da Medicina (SPDM), São Paulo, SP, Brazil.

Clarice Sandi Madruga et al. Braz J Psychiatry. 2024.

. 2024:46:e20233234.

doi: 10.47626/1516-4446-2023-3234. Epub 2024 Jun 21.

¹ Associação Paulista para o Desenvolvimento da Medicina (SPDM), São Paulo, SP, Brazil. Departamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
² Associação Paulista para o Desenvolvimento da Medicina (SPDM), São Paulo, SP, Brazil.

No abstract available

Conflict of interest statement

The authors report no conflicts of interest.

1. Souza JDR, Madruga CS, Noto C. Emerging synthetic cannabinoids and the risk of psychosis: a growing concern for public health. Braz J Psychiatry. 2023;45:306. - PMC - PubMed
1. Gatch MB, Tourigny A, Shetty RA, Forster MJ. Behavioral pharmacology of five novel synthetic cannabinoids. Behav Pharmacol. 2022;33:175–83. - PMC - PubMed
1. Manso BP, Dias CN. A guerra: a ascensão do PCC e o mundo do crime organizado no Brasil. São Paulo: Todavia; 2018.
1. Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol. 2015;29:698–703. - PubMed
1. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131:106–11. - PubMed